Mer­ck, Ei­sai notch full ap­proval for Keytru­da-TKI in­hibitor com­bo in ad­vanced en­dome­tri­al can­cer

Mer­ck PD-1 in­hibitor Keytru­da has been in the hot seat as the FDA ri­fles through its ac­cel­er­at­ed ap­proval pro­gram for drugs that even­tu­al­ly flop con­fir­ma­to­ry stud­ies. But for a Keytru­da com­bo with an Ei­sai TKI in­hibitor in en­dome­tri­al can­cer, that won’t be an is­sue.

The FDA on Thurs­day gave its full ap­proval to a com­bi­na­tion of Keytru­da and TKI in­hibitor Lenvi­ma to treat sec­ond-line or lat­er pa­tients with ad­vanced en­dome­tri­al car­ci­no­ma with­out a ge­net­ic mis­match re­pair de­fi­cien­cy or high mi­crosatel­lite in­sta­bil­i­ty, the drug­mak­ers said Thurs­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER